Green Cross announced Wednesday that its operating profit in the second quarter of this year amounted to 34.5 billion won ($31 million), up 43.6 percent from the same period of last year.

Its sales also increased 8.8 percent from a year earlier to hit the record high of 330.2 billion won.

Green Cross_녹십자 (CEO Huh Eun-chul_허은철) ascribed the record-high quarterly sales the brisk sales of its blood products and vaccines, which marked the year-on-year growth of 12.1 percent and 37.8 percent, respectively.

The exports of influenza vaccines and immunoglobulin took the lead in the expanding the company’s overseas sales, marking sales increase rates of 9 percent.

Also contributing to the improved profitability of Green Gross were the drops in the share of marketing and management costs against turnover, the company said. Net profit increased 59.2 percent to 26.9 billion won.

“Our brisk performance at home will continue in the second half of this year when we supply flu vaccines to the domestic market, and the export of varicella vaccine to Latin America will be reflected on the results from the third quarter,” a company official said.